ClinicalTrials.gg
RecruitingNCT04864145SEASON-ARUpdated Apr 8, 2026

Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation

An interventional study of Transcatheter Aortic Valve Implantation and Medical therapy in Aortic Valve Disease, sponsored by Nanjing First Hospital, Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Nanjing First Hospital, Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Aortic Valve Disease with a site in China — 16 open to participants now, 18 under way, none of them phase 3. Aortic Valve Disease · China.

Planned enrollment
3rd of 14
210 · median 98
Started
2021
with 3 others
No phase
12 of 27
4 open now
Primary completion
2026-12
later than 6 of 17 live
Registered
6th of 27
by date
Lead sponsor
2 of 27
Nanjing First Hospital, Nanjing Medical University

Among the 27 studies in Aortic Valve Disease with a site in China, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2021, is one of 12 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 6th registered.

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

16 of the 27 studies in Aortic Valve Disease with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Aortic Valve Disease with a site in China, or all of them as a file.
02

Study summary

Prospective, multicenter, randomized trial.

Read the detailed description

Patients with severe native aortic valve regurgitation (AR) who have symptoms, impaired LVEF (≤55%) or left ventricular enlargement have the indications for surgery. According to data from the Euro Heart Survey, only 21.8% with LVEF 30-50% and 2.7% with LVEF \<30% were referred for surgical aortic valve replacement (SAVR) among patients with severe native aortic regurgitation. Advanced age and comorbidities were often considered as main reasons to refuse SAVR. The annual mortality of untreated patients with severe AR is 10-20%. Pure native AR is always an exclusion criterion in all randomized controlled trials on transcatheter aortic valve implantation (TAVR) because the specific anatomical features can preclude adequate valve implantation. Several small, retrospective studies showed that off-label use of TAVR appears to be a feasible treatment choice for AR patients at high risk for SAVR. The present study aims to investigate the use of TAVR in AR patients.

03

Conditions studied

  • Aortic Valve Disease

Browse trials for

04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Procedural indications: symptomatic severe aortic regurgitation; no symptom plus ≤ 55% or left ventricular end-diastolic dimension (LVEDD) > 65mm or left ventricular end-systolic dimension (LVESD) > 50mm;
  2. Severe aortic valve regurgitation, and mean pressure gradient \< 20mmHg; Annular perimeter ≤ 85 mm;
  3. The ratio of the perimeter of the left ventricular outflow tract 4mm to the perimeter of the valve annulus is 0.95-1.05;
  4. STS score ≥8 or moderate to severe frailty or refused surgical valve replacement or presence of any of the following factors judged to be difficult to perform the surgical valve replacement:

    1. Severe aorta calcification or active ascending aorta atherosclerotic plaque
    2. History of mediastinum radiotherapy
    3. Past mediastinitis
    4. Presence of unobstructed coronary bypass implants
    5. Previous more than two cardiothoracic surgeries
    6. Liver cirrhosis
    7. Other surgical risk factors

Exclusion criteria

Exclusion Criteria:

  1. Age \< 60 years old;
  2. Ascending aorta diameter >45mm;
  3. Coronary multi-vessel disease (SYNTAX score >32);
  4. \<1 year;
  5. \<30%;
  6. Acute myocardial infarction within 30 days;
  7. Allergies or to related drugs (aspirin, clopidogrel, warfarin, or contrast agents);
  8. Other situations judged by the researcher as unsuitable for participating in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Active comparator
    Medical therapy

    Patients in medical therapy will receive conservative care, mainly including angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.

    Drug: Medical therapy

  • Experimental
    Transcatheter Aortic Valve Implantation

    Patients in TAVR group will receive transcatheter aortic valve replacement.

    Device: Transcatheter Aortic Valve Implantation

Interventions

  • DeviceTranscatheter Aortic Valve Implantation

    The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.

    Also known as: The VitaFlow™ system (MicroPort®, Shanghai, China)

  • DrugMedical therapy

    Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.

    Also known as: Optimal medical therapy

06

What researchers measure

Primary outcomes

  1. Clinical worsening

    A composite of all cause death, disabling stroke, or heart failure rehospitalization

    Time frame: 12 months

Secondary outcomes

  1. Procedural complications

    Any aortic dissection, annular rupture, coronary artery occlusion, vascular complications, permanent pacemaker implantation.

    Time frame: 12 months

  2. 6-minute walk distance

    This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.

    Time frame: 12 months

  3. New York Heart Association (NYHA) functional class

    Classification of function capacity of the NYHA.

    Time frame: 12 months

  4. Stroke

    Stroke is defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction.

    Time frame: 12 months

  5. Mortality

    All-cause, cardiovascular, and non-cardiovascular mortality

    Time frame: 12 months

  6. Bleeding Complications

    The original VARC definitions with BARC classifications

    Time frame: 12 months

  7. Prothetic valve dysfunction

    Any prothetic aortic valve stenosis, prothesis-patient mismatch, prosthetic aortic valve regurgitation

    Time frame: 12 months

  8. Rehospitalization

    Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2026, 67 months after the start.

Of 61 interventional studies with no phase under Aortic Valve Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 61. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2021
First posted
Apr 28, 2021
StartActual
May 21, 2021
Primary completionEst.
Dec 30, 2026
CompletionEst.
May 30, 2031
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04864145
Responsible party
Shaoliang Chen, MD (Director of Cardiology and Cath Lab, Vice President of Nanjing First Hospital, Nanjing First Hospital, Nanjing Medical University) — Principal investigator
First posted
Apr 28, 2021
Start date
May 21, 2021
Primary completion
Dec 30, 2026 (estimated)
Completion
May 30, 2031 (estimated)
Last update
Apr 8, 2026

Study contacts

Jun-Jie Zhang, MD, PhD
Contact
jameszll@163.com
+86-25-52271350
Jing Kan, MPH
Contact
kanjingok@126.com
+86-25-52271398
Shao-Liang Chen, MD, PhD
study chair · Nanjing First Hospital, Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion